Share on Facebook Share on Twitter Share on LinkedIn Share on Google+ Share by Email

Skip to content

Key resources

  • Bibliography
  • Health promotion
    Health promotion
  • Health practice
    Health practice
  • Yarning places
    Yarning places
  • Programs
  • Organisations
  • Conferences
  • Courses
  • Funding
  • Jobs
Australian Indigenous HealthBulletin

Bronchiectasis exacerbation study trial part 1 and 2 (BEST)



The Bronchiectasis exacerbation study trial (BEST) is being undertaken at five major hospitals around Australia, to provide more evidence as to whether antibiotics are necessary for all exacerbation caused by non-cystic fibrosis (CF) bronchiectasis. Bronchiectasis is recognised as a significant disorder which affects Indigenous and non-Indigenous children and adults living in urban and remote Australia. It is increasingly diagnosed in children and adults with difficult asthma and chronic cough. Effective management of bronchiectasis, particularly prevention of severe exacerbations, is associated with improved long term lung function.

The objectives of the study are:

This study will add to the body of evidence regarding the use of antibiotics to prevent exacerbations caused by non-CF bronchiectasis. The study commenced in 2012 and is scheduled for completion in 2014 and is funded by the National Health and Medical Research Council (NHMRC).

Adapted from Menzies School of Health Research



Related publications

Chang AB, Grimwood K, Wilson AC, van Asperen PP, Byrnes CA, O’Grady KF, Sloots TP, Robertson CF, Torzillo PJ, B McCallum GB, Masters IB, Buntain HM, Mackay IM, Ungerer J, Tuppin J, Morris PS (2013)

Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Trials; 14: 53

Retrieved 20 February 2013 from


Last updated: 10 March 2014
Return to top